A pilot open study of long term high dose creatine augmentation in patients with treatment resistant negative symptoms schizophrenia
Levental U, Bersudsky Y, Dwalatzky T, Lerner V, Medina S, Levine J
The Israel journal of psychiatry and related sciences · 4 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2015-01-01 · Isr J Psychiatry Relat Sci · vol. 52 · issue 1 · pp. 6–10
- Publisher
- National Institutes of Health
- Cited
- 7 citations · more than 66% of similar papers · 0.4× the field average
- References
- 0 works
- Access
- Paywalled
- Research areas
- Diet and metabolism studies · Muscle metabolism and nutrition
- Keywords
- Schizophrenia (object-oriented programming), Parkinsonism, Creatine, Medicine, Cognition, Psychology, Internal medicine, Psychiatry, Physical therapy
- MeSH
- humans, creatine, antipsychotic agents, treatment outcome, schizophrenia, drug synergism, drug resistance, adult, middle aged, female, male, cognitive dysfunction
6 authors
From IL
- U LeventalBen-Gurion University of the Negev
- Yuly BersudskyBen-Gurion University of the Negev
- T DwalatzkyBen-Gurion University of the Negev
- Vladimir LernerBen-Gurion University of the Negev
- Sarah MedinaBen-Gurion University of the Negev
- Jay F. LevineBen-Gurion University of the Negev
Abstract
Background
The effects of creatine on brain metabolism and the potential cognitive enhancing properties of this compound raise the possibility of developing a new augmentation therapeutic strategy in schizophrenia especially in patients demonstrating negative and cognitive symptomatology.
Methods
Seven inpatients with chronic schizophrenia presenting with treatment resistant negative symptoms were enrolled into exploratory treatment study with creatine monohydrate augmentation at a daily high-dose of 10 grams, administered for 6 months. Several clinical rating scales and a computerized cognitive assessment battery were applied.
Results
Creatine treatment mildly improved the schizophrenia symptomatology but there were no significant changes in cognitive functions. Several ward behaviors were also improved. Tardive parkinsonism improved numerically by above 40% in 4 out of 6 patients.
Conclusion
This small, open design study of high dose creatine add-on for 6 months in chronic inpatients with schizophrenia demonstrated only mild positive effects on the patients' symptomatology and behavior and might have beneficial effect on tardive parkinsonism.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.